PRKCD

PRKCD is a serine/threonine protein kinase that operates as a context-dependent regulator of apoptosis, autophagic/mitophagic flux, and cellular stress responses, with downstream actions dictated by its phosphorylation targets and subcellular localization (PMID:34671015, PMID:35001811, PMID:25419709). In B cells, PRKCD initiates apoptosis by phosphorylating both the SCF substrate adaptor FBXO25 and the pro-survival protein HAX-1, directing nuclear FBXO25 to mitochondrial HAX-1 to drive SCF(FBXO25)-mediated ubiquitination and degradation of HAX-1 (PMID:25419709). At mitochondria, PRKCD kinase activity is required for PRKN-independent mitophagy, where it facilitates recruitment of ULK1/ATG13 to early autophagic structures while remaining dispensable for PRKN-dependent mitophagy and starvation-induced autophagy (PMID:34671015, PMID:35001811). In contrast, in stressed kidney tubule cells PRKCD restrains cytoprotective autophagy through an AKT–MTOR cascade that represses ULK1, thereby promoting cell death (PMID:28059582). PRKCD activity also drives cancer cell invasion: phosphorylation at Y313 activates Src and p38 MAPK to promote proliferation and metastasis (PMID:38347536). PRKCD abundance is tightly controlled at multiple levels—K48-linked polyubiquitination by TRIM69 targets it for proteasomal degradation (PMID:37864033), transcriptional input from Foxg1 and the ATF4/NSUN7 (mRNA 5-methylcytosine) axis sets its expression (PMID:38085455, PMID:41850512), and miR-181a represses it via its 3'-UTR (PMID:22847611, PMID:24183997). Across genetic mouse models PRKCD additionally shapes ferroptosis, MMP13-driven cartilage degeneration, and pain signaling in a tissue-specific manner (PMID:38704083, PMID:37890601).

1. 2014 High

   Established a direct molecular route by which PRKCD initiates apoptosis, resolving how a kinase couples to controlled destruction of a pro-survival factor.

   Evidence Unbiased substrate screen, phosphorylation and Co-IP assays, phosphodegron mutants, and Eµ-Myc/MCL xenotransplant models

   PMID:25419709

   Open questions at the time

   • Does not define whether the same FBXO25/HAX-1 axis operates outside B-cell lineages
   • Upstream activator of PRKCD in this apoptotic context not resolved
2. 2017 Medium

   Placed PRKCD upstream of an AKT–MTOR–ULK1 cascade that suppresses cytoprotective autophagy, framing PRKCD as a pro-death modulator of autophagy in stressed epithelium.

   Evidence Cell-based assays with pharmacological and genetic PRKCD manipulation and phosphorylation pathway analysis in cisplatin-treated kidney tubule cells

   PMID:28059582

   Open questions at the time

   • Direct kinase-substrate relationship between PRKCD and AKT not biochemically reconstituted
   • Summarized largely as commentary without full methodological detail
3. 2021 High

   Defined a distinct mitochondrial role for PRKCD in PRKN-independent mitophagy, separating it from canonical PRKN-dependent and starvation-induced autophagy.

   Evidence siRNA screen, kinase-dead mutants, subcellular fractionation, in vitro mitophagy assays, and C. elegans/zebrafish knockouts

   PMID:34671015 PMID:35001811

   Open questions at the time

   • Direct PRKCD substrates at the mitochondrion driving ULK1/ATG13 recruitment not identified
   • Mechanism reconciling pro-mitophagy versus autophagy-suppressing roles unresolved
4. 2023 Medium

   Identified post-translational and transcriptional controls over PRKCD abundance, showing its protein levels and signaling output are set by TRIM69 ubiquitination and Foxg1 transcription.

   Evidence Reciprocal Co-IP/MS, ubiquitination and domain-mapping assays (TRIM69), and RNA-seq plus dual-luciferase and AAV knockdown (Foxg1)

   PMID:37864033 PMID:38085455

   Open questions at the time

   • Whether TRIM69 regulates PRKCD outside gastric cancer is unknown
   • How these regulatory inputs are coordinated in a given cell is unaddressed
5. 2024 Medium

   Linked a specific PRKCD tyrosine phosphorylation event to oncogenic signaling, identifying Y313 as the trigger for Src/p38 MAPK activation and invasion.

   Evidence Phosphoproteomic profiling, Y313F mutagenesis, gain-of-function assays, and xenograft models in triple-negative breast cancer

   PMID:38347536

   Open questions at the time

   • Kinase responsible for Y313 phosphorylation not identified
   • Direct versus indirect activation of Src/p38 not distinguished
6. 2024 Medium

   Extended PRKCD's physiological footprint into ferroptosis and tissue-specific pain/cartilage phenotypes through genetic loss-of-function studies.

   Evidence Global and conditional Prkcd knockout mice with histopathology, immunofluorescence, electron microscopy, and behavioral readouts

   PMID:37890601 PMID:38704083

   Open questions at the time

   • Molecular substrates linking PRKCD to Hippo/ferroptosis and MMP13 regulation not defined
   • Opposing effects across cell types complicate a unified mechanism
7. 2026 Medium

   Characterized translational and epigenetic control of PRKCD expression via the ATF4/NSUN7 m5C axis, adding mRNA modification to its regulatory layers in neurotoxicity.

   Evidence Dot blot, RIP, dual-luciferase, ChIP assays, and NSUN7 knockout mice

   PMID:41850512

   Open questions at the time

   • Generalizability of NSUN7-mediated PRKCD regulation beyond sevoflurane neurotoxicity unknown
   • Downstream PRKCD substrates driving mitochondrial fission not identified

• How PRKCD's opposing roles—pro-apoptotic versus pro-mitophagy, autophagy-suppressing versus tissue-protective—are selected within a single cell remains unresolved.
• No unified model linking localization, phosphorylation state, and downstream pathway choice
• Direct mitochondrial substrates and the determinants of context-specificity not identified